Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The ABO Blood Group01:12

The ABO Blood Group

2.1K
The ABO blood group system is a critical element of transfusion medicine, essential for determining blood compatibility in transfusions and organ transplants. It is based on specific antigens, or agglutinogens, present on the surface of red blood cells (RBCs) and corresponding antibodies, or agglutinins, in the blood plasma.
Antigens in the ABO Blood Group System
Antigens are substances that can trigger an immune response, leading to the production of antibodies. In the ABO blood group system,...
2.1K
Blood Types02:20

Blood Types

18.2K
Human blood is classified into different types based on the presence of antigens on the red blood cell's surface and antibodies in the plasma. Proper identification of blood type is essential for successful blood transfusion. The International Society of Blood Transfusion has identified 38 human blood types based on the surface antigens on the red blood cells. The most common types are ABO, Rh, and MNS blood types.
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...
18.2K
Disorders of Hemostasis01:24

Disorders of Hemostasis

1.2K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.2K
Blood Transfusion01:15

Blood Transfusion

793
Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
793
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

11.1K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
11.1K
Blood Typing01:10

Blood Typing

1.4K
Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Popping FVIII concentrates into an updated classification.

Blood advances·2026
Same author

Integration of Efanesoctocog Alfa in Clinical Practice for Children, Adolescents, and Young Adults With Severe Haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study.

Haemophilia : the official journal of the World Federation of Hemophilia·2025
Same author

Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis.

Blood advances·2025
Same author

A literature review of major surgery experience with emicizumab in people with hemophilia A without factor VIII inhibitors.

Research and practice in thrombosis and haemostasis·2025
Same author

2025 Clinical Trials Update on Hemophilia, VWD, and Rare Inherited Bleeding Disorders.

American journal of hematology·2025
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Related Experiment Video

Updated: Sep 6, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K

Hemophilia A/B.

Stacy E Croteau1

  • 1Boston Children's Hospital, Boston Hemophilia Center, 300 Longwood Avenue, Boston, MA, USA.

Hematology/Oncology Clinics of North America
|June 30, 2022
PubMed
Summary
This summary is machine-generated.

Adeno-associated virus gene therapy can improve clotting factor levels in hemophilia patients, reducing bleeding and improving quality of life. Further research into immune responses and alternative gene therapy methods like lentiviral vectors and CRISPR/Cas-9 is ongoing.

Keywords:
AAV vectorFactor IXFactor VIIIGene therapyHemophilia

More Related Videos

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.4K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.4K

Related Experiment Videos

Last Updated: Sep 6, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

6.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.4K
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.4K

Area of Science:

  • Gene Therapy
  • Hematology
  • Molecular Biology

Background:

  • Adeno-associated virus (AAV)-mediated gene transfer has shown promise in treating severe hemophilia by increasing Factor VIII (FVIII) or Factor IX (FIX) activity.
  • Elevated FVIII/IX levels (above ~15 IU/dL) correlate with reduced bleeding events and decreased reliance on factor concentrates, enhancing patient quality of life.

Purpose of the Study:

  • To review the current state and challenges of AAV-mediated gene therapy for hemophilia.
  • To explore the impact of immune responses and hepatocyte expression on gene therapy efficacy.
  • To discuss potential advancements with lentiviral (LV) and CRISPR/Cas-9 gene therapy approaches.

Main Methods:

  • Review of existing literature on AAV gene therapy for hemophilia.
  • Analysis of factors influencing transgene expression and durability.
  • Discussion of emerging gene editing and vector technologies.

Main Results:

  • AAV gene therapy has successfully increased FVIII/FIX levels in adults with severe hemophilia, leading to clinical benefits.
  • Variability in therapeutic outcomes is linked to immune responses and hepatocyte gene expression.
  • Lentiviral and CRISPR/Cas-9 technologies offer potential for broader eligibility and improved expression.

Conclusions:

  • AAV gene therapy represents a significant advancement in hemophilia treatment, offering reduced bleeding and improved quality of life.
  • Addressing immune responses and optimizing transgene expression are crucial for long-term success.
  • Next-generation gene therapy platforms hold promise for further enhancing treatment efficacy and accessibility.